)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Whitehawk Therapeutics
Whitehawk Therapeutics (WHWK) investor relations material
Whitehawk Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary12 Mar, 2026
Executive summary
Advanced two antibody-drug conjugates (HWK-007 and HWK-016) into active Phase 1 trials, targeting PTK7 and MUC16 in various cancers.
Appointed a new Chief Medical Officer with extensive oncology experience.
Presented data confirming PTK7 as a highly expressed, clinically relevant tumor marker.
Financial highlights
Cash, cash equivalents, and short-term investments totaled $145.7M at year-end 2025, up from $47.2M at year-end 2024.
Net loss for Q4 2025 was $23.3M, compared to $18.3M in Q4 2024.
Full-year 2025 net loss was $20.6M, significantly improved from $63.7M in 2024, aided by an $87.3M gain from the divestiture of a subsidiary.
Revenue for 2025 was $25.98M, up from $5.87M in 2024.
Outlook and guidance
Cash reserves expected to fund operations into 2028.
IND submission for HWK-206 planned for mid-2026, with Phase 1 trial recruitment to start in Q3 2026.
Initial Phase 1 results for HWK-007 and HWK-016 anticipated in 1H 2027.
Preclinical data across the portfolio to be presented in Spring 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Whitehawk Therapeutics
- Three differentiated ADCs progress toward key clinical milestones, with data expected by early 2027.WHWK
The Citizens Life Sciences Conference 202610 Mar 2026 - Three differentiated ADCs advance in parallel, targeting broad cancer indications with strong stability and safety.WHWKTD Cowen 46th Annual Health Care Conference3 Mar 2026
- Advancing three differentiated ADCs with clinical data expected in 2027 and strong cash runway.WHWKOppenheimer 36th Annual Healthcare Life Sciences Conference25 Feb 2026
- Next-gen ADCs show superior preclinical results, with clinical data expected in early 2027.WHWKJefferies London Healthcare Conference 20253 Feb 2026
- FYARRO sales rose 15% sequentially; cash runway extends into Q4 2025 as trials advance.WHWKQ2 20242 Feb 2026
- PRECISION1's interim data in Q3 could expand reach beyond PEComa, with pipeline trials progressing.WHWKJefferies 2024 Global Healthcare Conference1 Feb 2026
- $100M FYARRO sale, $100M PIPE, and ADC in-licensing drive late 2028 runway and clinical focus.WHWKInvestor Update10 Jan 2026
- Transformed into an ADC-focused company with robust funding and three INDs planned in 15 months.WHWKQ4 202426 Dec 2025
- Oncology company pivots to ADC pipeline after $100M raise and asset sale; investors register shares.WHWKRegistration Filing16 Dec 2025
Next Whitehawk Therapeutics earnings date
Q1 20266 May, 2026
Whitehawk Therapeutics
Next Whitehawk Therapeutics earnings date
Q1 20266 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage